Inspire Will Use Allergy Expertise To Develop Phase III Antihistamine Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Inspire acquires the rights to FAES’ bilastine for the treatment or prevention of allergic rhinitis.
You may also be interested in...
Inspire Terminates Deal With FAES Farma For Oral Bilastine
Company ends collaboration following a meeting with FDA last year in which the agency recommended additional clinical trial work.
Inspire Terminates Deal With FAES Farma For Oral Bilastine
Company ends collaboration following a meeting with FDA last year in which the agency recommended additional clinical trial work.
Inspire Will Market AzaSite With 98-Rep Sales Force
Company announces agreement with InSite Vision to license bacterial conjunctivitis treatment pending at FDA with a late April user fee date.